<div id="readability-page-1"><p><span>Amgen (NASDAQ:AMGN - Get Free Report)</span> was upgraded by equities researchers at Wall Street Zen from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a note issued to investors on Monday.</p><ul><li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li></ul><p>Other analysts have also recently issued reports about the stock. Morgan Stanley decreased their price target on shares of Amgen from $329.00 to $304.00 and set an &#34;equal weight&#34; rating for the company in a research report on Friday. The Goldman Sachs Group  reiterated a &#34;buy&#34; rating on shares of Amgen in a research note on Tuesday, November 25th. Citigroup raised their target price on Amgen from $310.00 to $315.00 and gave the company a &#34;neutral&#34; rating in a report on Wednesday, September 24th. HSBC  restated a &#34;buy&#34; rating and issued a $425.00 price target on shares of Amgen in a report on Wednesday. Finally, Truist Financial began coverage on shares of Amgen in a research note on Monday, November 24th. They set a &#34;hold&#34; rating and a $318.00 price objective on the stock. One research analyst  has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have given a Hold rating and one  has assigned  a Sell rating to the company. Based on data from MarketBeat, the stock  has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $332.85.</p><p><b>Check Out Our Latest Report on AMGN</b></p><h2>Amgen Stock Up 0.1%</h2><ul><li>Amgen Stock: New All-Time Highs Ahead After Earnings Beat</li></ul><p>AMGN opened at $317.74 on Monday. Amgen has a 1 year low of $253.30 and a 1 year high of $346.38. The firm has a 50 day moving average price of $316.12 and a 200 day moving average price of $298.92. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.99 and a current ratio of 1.28. The company has a market cap of $171.10 billion, a PE ratio of 24.55, a price-to-earnings-growth ratio of 2.87 and a beta of 0.45. </p><p>Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating analysts' consensus estimates of $5.01 by $0.63. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The firm had revenue of $9.56 billion for the quarter, compared to analysts' expectations of $8.98 billion. During the same period in the previous year, the company posted $5.58 earnings per share. Amgen's revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS.  Sell-side analysts expect that  Amgen will post 20.62 earnings per share for the current year. </p><h2>Insider Buying and Selling at Amgen</h2><ul><li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li></ul><p>In other news, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the transaction, the senior vice president owned 7,225 shares of the company's stock, valued at approximately $2,436,703.50. This trade represents a 30.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the transaction, the executive vice president owned 41,923 shares of the company's stock, valued at $14,120,924.09. This trade represents a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 10,908 shares of company stock worth $3,674,966 in the last ninety days. 0.69% of the stock is owned by insiders. </p><h2>Institutional Inflows and Outflows</h2><p>Several hedge funds have recently made changes to their positions in AMGN. West Family Investments Inc. boosted its holdings in  Amgen by 1.1% in the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company's stock worth $779,000 after purchasing an additional 30 shares during the period.  Viawealth LLC raised its holdings in shares of  Amgen by 0.4% during the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company's stock worth $2,023,000 after purchasing an additional 30 shares during the period.  LOM Asset Management Ltd lifted its position in shares of  Amgen by 1.2% in the 3rd quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company's stock worth $721,000 after buying an additional 30 shares during the last quarter.  Sittner &amp; Nelson LLC boosted its holdings in shares of  Amgen by 0.4% in the 3rd quarter. Sittner &amp; Nelson LLC now owns 7,276 shares of the medical research company's stock valued at $2,053,000 after buying an additional 30 shares during the period.  Finally, TAGStone Capital Inc. grew its position in shares of  Amgen by 0.8% during the 3rd quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company's stock valued at $1,157,000 after buying an additional 32 shares during the last quarter. Institutional investors and hedge funds own  76.50% of the company's stock. </p><h2>Amgen Company Profile</h2> (Get Free Report)<p>Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Amgen</li><li>High Flyers: 3 Natural Gas Stocks for March 2022</li><li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li><li>What is a Dividend King? </li><li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li><li>Upcoming IPO Stock Lockup Period, Explained</li><li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Amgen Right Now?</h2><p>Before you consider Amgen, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p><p>While Amgen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AMGN

<p>Wall Street Zen upgraded Amgen's stock rating from "buy" to "strong-buy." Other analysts have mixed ratings, with Morgan Stanley lowering its price target and Citigroup raising it. Amgen's stock opened at $317.74, with a market cap of $171.10 billion. Recent insider sales were disclosed, and institutional investors have adjusted their positions. Amgen reported strong quarterly earnings, beating estimates, and set its FY 2025 EPS guidance at 20.600-21.400.</p>

Amgen (NASDAQ:AMGN) Upgraded to Strong-Buy at Wall Street Zen